Physician profile
Kevin E Tourt
NPI 1891542882
$3,932.39
in general payments reported to CMS, 2019-2025
27 companies · $2,639 in 2025
The $2,639 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,293 · 2025: $2,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,932.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,280.23 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $419.83 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $260.23 | 2024-2025 | |
| Amgen INC. | $250.67 | 2025 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $212.48 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.15 | 2024-2025 | Xifaxan |
| Lundbeck LLC | $150.37 | 2024-2025 | Rexulti |
| Pfizer INC. | $126.47 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $124.99 | 2024 | |
| Astellas Pharma US INC | $124.89 | 2024 | Veozah |
| Exact Sciences Corporation | $123.80 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.86 | 2024-2025 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $104.10 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $87.28 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $69.60 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.96 | 2024-2025 | Caplyta |
| Shield Therapeutics INC | $50.97 | 2024-2025 | |
| Dexcom, INC. | $35.26 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $31.91 | 2025 | Korlym |
| Amneal Pharmaceuticals LLC | $29.60 | 2024 | Unithroid |
| Tactile Systems Technology INC | $23.70 | 2024 | Entre Plus, Flexitouch Plus |
| Abbott Laboratories | $20.55 | 2025 | Freestyle Libre 3 |
| Amphastar Pharmaceuticals, INC. | $20.14 | 2025 | |
| Xeris Pharmaceuticals, INC. | $20.12 | 2025 | Keveyis |
| Ibsa Pharma INC. | $17.52 | 2024 | Licart, Tirosint |
| Seqirus USA INC | $17.29 | 2025 | Fluad, Flucelvax |
| Boston Scientific Corporation | $16.42 | 2024 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Tourt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.